文献速递前列腺癌

转移性去势抵抗性前列腺癌中AKT1和PIK3CA激活突变的研究

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2020-05-22

本研究分析了599例循环肿瘤DNA含量>2%的转移性前列腺癌患者的cfDNA测序数据,发现6.0%(36/599)携带AKT1或PIK3CA体细胞克隆激活突变。这些突变定义了具有低水平AR拷贝增益的独特mCRPC分子亚型,且一例AKT1突变患者对Akt抑制剂ipatasertib单药治疗出现50%的PSA下降。

要点

  • mCRPC中AKT1/PIK3CA激活突变发生率为6.0%,可通过cfDNA检测识别。
  • AKT1/PIK3CA突变型mCRPC的AR基因拷贝数中位4.7,低于野生型的10.3(p=0.003)。
  • AKT1突变与PTEN改变互斥,且一例患者对ipatasertib单药有PSA应答。

核心结论

  • AKT1/PIK3CA激活突变在mCRPC中相对常见,界定了一个具有低水平AR拷贝增益的独特分子亚型。
  • 克隆性流行和突变等位基因选择证据提示部分患者存在PI3K通路依赖性。
  • cfDNA筛查有助于前瞻性临床试验测试PI3K通路抑制剂。

研究设计与样本

  • 靶向cfDNA测序分析599例循环肿瘤DNA含量>2%的转移性前列腺癌患者。
  • 对AKT1/PIK3CA突变患者进行PTEN内含子测序,并在可能时分析匹配的诊断肿瘤组织。

主要发现

  • 6.0%(36/599)患者携带AKT1或PIK3CA体细胞克隆激活突变。
  • 突变等位基因特异性失衡常见,克隆突变通常在治疗前原发组织中检测到,且在系列ctDNA中一致。
  • AKT1/PIK3CA突变型mCRPC的AR基因拷贝数中位4.7,低于野生型的10.3(p=0.003)。
  • AKT1突变与PTEN改变互斥。
  • AKT1/PIK3CA突变患者与野生型患者在接受标准治疗时临床结局相似。

临床怎么用

  • 可通过cfDNA筛查识别AKT1/PIK3CA激活突变的mCRPC患者,用于筛选适合PI3K通路抑制剂临床试验的候选人。

局限性

  • 无法在ctDNA阴性患者中评估AKT1/PIK3CA的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic castration-resistant prostate cancer (mCRPC), but are linked to activation of phosphatidylinositol 3-kinase (PI3K) signalling and sensitivity to pathway inhibitors in other cancers. OBJECTIVE: To determine the prevalence, genomic context, and clinical associations of AKT1/PIK3CA activating mutations in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: We analysed targeted cell-free DNA (cfDNA) sequencing data from 599 metastatic prostate cancer patients with circulating tumour DNA (ctDNA) content above 2%. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In patients with AKT1/PIK3CA mutations, cfDNA was subjected to PTEN intron sequencing and matched diagnostic tumour tissue was analysed when possible. RESULTS AND LIMITATIONS: Of the patients, 6.0% (36/599) harboured somatic clonal activating mutation(s) in AKT1 or PIK3CA. Mutant allele-specific imbalance was common. Clonal mutations in mCRPC ctDNA were typically detected in pretreatment primary tissue and were consistent across serial ctDNA collections. AKT1/PIK3CA-mutant mCRPC had fewer androgen receptor (AR) gene copies than AKT1/PIK3CA wild-type mCRPC (median 4.7 vs 10.3, p = 0.003). AKT1 mutations were mutually exclusive with PTEN alterations. Patients with and without AKT1/PIK3CA mutations showed similar clinical outcomes with standard of care treatments. A heavily pretreated mCRPC patient with an AKT1 mutation experienced a 50% decline in prostate-specific antigen with Akt inhibitor (ipatasertib) monotherapy. Ipatasertib also had a marked antitumour effect in a patient-derived xenograft harbouring an AKT1 mutation. Limitations include the inability to assess AKT1/PIK3CA correlatives in ctDNA-negative patients. CONCLUSIONS: AKT1/PIK3CA activating mutations are relatively common and delineate a distinct mCRPC molecular subtype with low-level AR copy gain. Clonal prevalence and evidence of mutant allele selection propose PI3K pathway dependency in selected patients. The use of cfDNA screening enables prospective clinical trials to test PI3K pathway inhibitors in this population. PATIENT SUMMARY: Of advanced prostate cancer cases, 6% have activating mutations in the genes AKT1 or PIK3CA. These mutations can be identified using a blood test and may help select patients suitable for clinical trials of phosphatidylinositol 3-kinase inhibitors.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Herberts C, Murtha AJ, Fu S, et al. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2020. PMID: 32451180. doi:10.1016/j.eururo.2020.04.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。